The FDA could gain several new powers when Congress examines drug safety reforms next year, including greater authority over prescription labels. Other changes could include requiring risk management plans for new drugs, establishing post-market PDUFA goals for safety issues, and clinical trial registration for Phase II, III and IV studies.

Related Summaries